SWOG clinical trial number
S9718

A Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Gemcitabine + CDDP in SCLC
Activated
07/01/1998
Closed
06/15/1999

Research committees

Lung Cancer

Publication Information Expand/Collapse

2007

Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718 [PMID: 17473660]

PJ Hesketh;K Chansky;V Israel;RT Grapski;TM Mekhail;CH Spiridonidis;GM Mills;K Kelly;JJ Crowley;DR Gandara Journal of Thoracic Oncology 2(5):440-444

2001

Southwest Oncology Group trial (SWOG) S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer (E-SCLC)

VP Israel;K Chansky;D Gandara Proc of the American Society of Clinical Oncology 20:316a(#1262)

2000

Gemcitabine and platinum combinations in advanced non-small cell lung cancer: an update

DR Gandara;MJ Edelman;P Lara;D Lau Lung Cancer 29(Suppl.2):7

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase